XENE SEC Filings, Earnings & Splits

Xenon Pharmaceuticals announced its financial results for the three and nine months ended September 30, 2026, via a press release furnished under Item 2.02 of Form 8-K.

Xenon Pharmaceuticals filed its quarterly 10-Q report for Q3 2026, disclosing financial results, cash position, and ongoing clinical development activities including its azetukalner program.

An institutional investor filed an amended Schedule 13G disclosing a passive ownership position in Xenon Pharmaceuticals Inc. The filing indicates a change in the holder's previously reported stake.

A Schedule 13G was filed regarding Xenon Pharmaceuticals Inc. (XENE), indicating a passive ownership position by an institutional or other holder. The filing text provided is only the EDGAR directory listing and does not include the substantive ownership details.

An institutional investor filed an amended Schedule 13G disclosing its passive ownership position in Xenon Pharmaceuticals Inc. (XENE).

Wellington Management Group LLP and affiliated entities filed a joint filing agreement as part of a Schedule 13G/A regarding their ownership of Xenon Pharmaceuticals common stock. The filing is an administrative amendment to a passive ownership disclosure.